68Ga-DOTA-FAPI-04

N/A

Report date: 2025/09/09 15:00:48

NME

Base Information

Drug Name68Ga-DOTA-FAPI-04

Drug Alias Name68Ga-DOTA-FAPI-04

ClassificationRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionFibroblast activation protein alpha inhibitors

TargetsProlyl endopeptidase FAP

Therapy Area/IndicationsNeuroendocrine Tumors

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesThe First Affiliated Hospital Of Xiamen University

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Michigan Rogel Cancer Center

Inactive CompaniesN/A

Active IndicationsNeuroendocrine Tumors

Inactive IndicationsN/A

Other Information

ATC CodeN/A